CD8A and lung carcinoma: Excitingly, we found out that our DC-CTL/CIK therapy significantly reduced several serological tumor markers such as AFP, CA199 and CA242 in primary liver cancer and CA724 in gastric cancer (p < 0.05), elevated the level of CD3+ CD8+ T cells in primary liver cancer and lung cancer (p < 0.05), and decreased the level of CD3+ CD4+ T cells in colon cancer, primary liver cancer and lung cancer (p < 0.05) and Treg cells in all types of tumors (p < 0.05), which indicated the promotion of immune functions in these patients.